Alexion adds fourth indication for C5 inhibitor Ultomiris in rare autoimmune disorder
AstraZeneca’s rare disease arm Alexion scored its fourth approval for Ultomiris in a rare autoimmune disorder after Phase 3 data showed there were zero patients with relapses over 73 weeks.
The FDA approved Ultomiris, the first and only long-acting C5 complement inhibitor, for the treatment of adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that affects the central nervous system and can relapse unpredictably. Symptoms can include blindness and neurological problems that can lead to permanent disabilities.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
